AngioDynamics (ANGO) revenue breakdown
By segment, Med Device is the largest at 53% of fiscal 2026 revenue; Med Tech grew fastest, 16% a year over 3 years.
By product, Med Device is the largest at 53% of fiscal 2026 revenue; Med Tech grew fastest, 22% a year over 5 years.
Revenue by segment
Fiscal years, as AngioDynamics reports them in its 10-K filings; fiscal 2026 total $320M.
| Segments | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|
| Med Device | $242M | $198M | $166M | $170M | 53% |
| Med Tech | $97M | $106M | $127M | $150M | 47% |
Revenue by product
Fiscal years, as AngioDynamics reports them in its 10-K filings; fiscal 2026 total $320M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Med Device | — | — | — | — | $235M | $238M | $242M | $198M | $166M | $170M | 53% |
| Med Tech | — | — | — | — | $56M | $79M | $97M | $106M | $127M | $150M | 47% |
| Endovascular Therapies | $129M | $120M | $120M | $113M | — | — | — | — | — | — | — |
| Vascular Access | $96M | $93M | $95M | $94M | — | — | — | — | — | — | — |
| Oncology Surgery | $45M | $49M | $56M | $57M | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as AngioDynamics reports them in its 10-K filings; fiscal 2026 total $320M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $224M | $214M | $217M | $208M | $237M | $266M | $283M | $251M | $251M | $275M | 86% |
| International | $46M | $48M | $54M | $56M | $54M | $50M | $56M | $52M | $42M | $45M | 14% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANGO.
Open ANGO in InvestinglyQuestions
Where does AngioDynamics make its money?
In fiscal 2026, by segment: Med Device $170M, Med Tech $150M.
From AngioDynamics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.